Drugs / mOPV1
mOPV1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05644184 | Mar 2023 → May 2026 overdue | poliomyelitis | PATH | Recruiting | No outcome recorded |
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT01586572 | Apr 2012 → May 2013 | poliomyelitis | Aga Khan University | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03722004 Comparator | Dec 2018 → Dec 2019 | poliomyelitis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mOPV1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05644184 ↗ |
| Known as | Monovalent oral poliovirus vaccine type 1 | “Monovalent oral poliovirus vaccine type 1 is a type-specific, live, attenuated oral poliovirus vaccine that protects against poliovirus type 1.” NCT03722004 ↗ |
| Known as | monovalent type-1 oral poliovirus vaccine | “monovalent type-1 oral poliovirus vaccine (mOPV1) given at shorter than usual intervals” PMID 26093979 ↗ Jun 2015 |
| Known as | Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 | “Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)” NCT05644184 ↗ |
| Modality | Vaccine | “Monovalent type 1 oral poliovirus vaccine (mOPV1)” NCT01586572 ↗ |
| Route | Oral | “Monovalent type 1 oral poliovirus vaccine (mOPV1)” NCT01586572 ↗ |